Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B
December 6, 2021
Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.
- Buyers
- Cyrus Biotechnology, Inc.
- Targets
- Orthogonal Biologics
- Industry
- Biotechnology
- Location
- Illinois, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioSyent Acquires Oral Science Inc.
March 2, 2026
Healthcare Services
BioSyent Inc. has successfully closed its previously announced acquisition of Oral Science Inc. for a total purchase price of $25.5 million. The deal was completed via a share purchase agreement dated February 8, 2026, with consideration paid through a mix of cash and BioSyent shares, and includes contingent earn-out and royalty payments.
-
Pharmaron Acquires 82.54% of Biortus Biosciences
October 28, 2025
Healthcare Services
Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.
-
Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Deal
October 11, 2025
Biotechnology
Bristol Myers Squibb (BMS) has entered into an agreement to acquire Orbital Therapeutics, a privately held biotechnology company developing RNA medicines. The $1.5 billion cash deal will give BMS Orbital’s lead candidate OTX-201 and its proprietary RNA platform, supporting BMS’s efforts to advance in vivo CAR T and immunotherapy approaches.
-
Bruker Corporation Acquires biocrates life sciences ag
June 3, 2025
Biotechnology
Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.
-
Bruker Corporation Acquires Canopy Biosciences, LLC
September 11, 2020
Biotechnology
Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.
-
Ligand Pharmaceuticals Acquires Crystal Bioscience
October 4, 2017
Biotechnology
Ligand Pharmaceuticals acquired Crystal Bioscience for $25 million in cash plus up to $10.5 million in milestones and revenue sharing, adding Crystal's chicken-derived HuMab (OmniChicken) antibody discovery platform and an in-house discovery lab. The acquisition (closing announced Oct 4, 2017) brings four fully-funded partnership programs, is expected to be accretive to revenue and earnings, and expands Ligand's OmniAb platform capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.